Trial reportFrontiers in aging2025
Trans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial.
Trial report in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- CaroRite™ for improving skin health and the visible signs of aging - a randomised, double-blind, placebo-controlled trial.Frontiers in aging · 2026Trial
- Skin Resilience and Biological Adaptability: Current Clinical Evidence on Micronutrients and Bioactive Compounds.Biomedicines · 2026Review
- Microbiome-Directed Bioactive Strategies in Skin Aging: Mechanistic Insights and Precision Nanocarrier Delivery Approaches.Molecules (Basel, Switzerland) · 2026Review
- Next-Generation Minimally Invasive Anti-Aging Therapy: Incorporation of Resveratrol-Nicotinamide Cerosomes into PLGA Microneedles for Enhanced Skin Permeation.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This double-blind, randomised, placebo-controlled clinical study evaluated the effects of trans-resveratrol on skin health. To date, and to the best of our knowledge, no study has tested trans-resveratrol as the only active ingredient, orally or topically, for improving skin parameters in humans. Therefore, the aim of this study was to investigate the effects of trans-resveratrol on skin health and visible signs of ageing, when administered orally and/or applied topically to the face. Methods: Healthy females aged 40 years and older were randomly assigned to one of four groups: placebo oral and topical (P/P Group), trans-resveratrol oral and placebo topical (A/P Group), placebo oral and trans-resveratrol topical (P/A Group), and trans-resveratrol oral and topical (A/A Group). Participants were instructed to take one capsule (75 mg trans-resveratrol) and apply 1 g of cream (1.5% trans-resveratrol) twice daily for 8 weeks. Outcome measures included wrinkle assessment, skin age, temperature, pore size, forehead lines, glabellar lines, Crow's feet, nasolabial folds, pigmentation, sebum levels, moisture, and elasticity, along with a self-assessment questionnaire, serum trans-resveratrol concentrations, and safety. Results: Out of 134 participants enrolled, 122 completed the study. Results indicated significantly reduced wrinkle scores in the A/A Group compared to the P/P Group at week 8. All treatment groups showed increased sebum levels, with the active topical groups (P/A and A/A Groups) having significantly higher U-zone sebum at week 8 compared to placebo topical groups (P/P and A/P Groups). No significant differences were found in other skin parameters. Serum trans-resveratrol conjugate levels increased significantly in the A/P and A/A Groups at week 4 and 8. All trial products were shown to be safe with minimal and only mild adverse events recorded in every group. Conclusion: Oral and topical trans-resveratrol treatment can help improve skin health parameters. When taken orally and applied topically, trans-resveratrol was effective at wrinkle reduction, and when applied topically, it increased sebum levels. Clinical Trial Registration: identifier ACTRN12621000709842.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.